Search
AG-858
go.drugbank.com/drugs/DB05502InvestigationalTumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.
DTX-101
go.drugbank.com/drugs/DB17699InvestigationalIt was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103] … DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene.
Coagulin-B
go.drugbank.com/drugs/DB17703Experimental[A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation
Retezorogant
go.drugbank.com/drugs/DB21592ExperimentalThe usage of the INN stem '-rogant' in the name indicates that Retezorogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and inverse agonist.
MaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalMaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Doramectin
go.drugbank.com/drugs/DB11400ExperimentalVet approvedDoramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
ND1251
go.drugbank.com/drugs/DB05132ExperimentalND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression.
Boldenone
go.drugbank.com/drugs/DB01541ExperimentalIllicitVet approvedIt is not indicated for use in humans in the US and is only available through veterinary clinics.
ATA-100
go.drugbank.com/drugs/DB18329InvestigationalATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a
REC-994
go.drugbank.com/drugs/DB15616InvestigationalREC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).